Author: admin

Genomic Profiling, African-American Women and Breast Cancer Risk

Gene Called USP9X and Tamoxifen Resistance

Metastatic Breast Cancer – ER-Positive – Dr. Eitan Amir summarizes the latest updates in ER positive breast cancer from the SABCS meeting in 2014

Biology and Pathology Insights – Dr. John Bartlett presented this session as a summary of the topic from original research presented at the SABCS 2014 session

Dr. John Bartlett Theranostic multiparametric tests improve residual risk assessment in early luminal breast cancer

Dr. Eileen Rakovitch A large prospectively-designed study of the DCIS score: Predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation – presented at the officially licensed Best of SABCS meeting in Toronto.

Surgical Oncology Highlights summarized from the San Antonio Breast Cancer Symposium sessions, and presented by Dr. Jean-Francois Boileau as part of the licensed Best of SABCS session in Toronto, in January 2015.

Radiation Oncology Highlights – Dr. Eileen Rakovitch summarizing top results from the San Antonio Breast Cancer Symposium

Advances in Early Breast Cancer (Chemotherapy and Targeted Therapy as well as Endocrine Therapy) are discussed by Dr. Maureen Trudeau from Sunnybrook Cancer Centre, Toronto, Canada

Neoadjuvant Treatment of Breast Cancer – A summary of the San Antonio Breast Cancer Symposium 2014, during the OncologyEducation licensed meeting in Canada, presented by Dr. Susan Dent

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Umberto Vitolo (Città della Salute e della Scienza di Torino, Turin, Italy) discusses recent advances in the management of mantle cell lymphoma, including a maintenance approach for young patients and ibrutinib therapy for relapsed patients.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent studies of the Bruton’s tyrosine kinase inhibitor, ibrutinib, in mantle cell lymphoma (MCL), including in patients with relapsed or refractory MCL who progress after bortezomib therapy and mutational analysis of these patients with primary resistance to ibrutinib, and ibrutinib in combination with rituximab.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses recent investigational advances in chimeric antigen receptor (CAR) T-cell immunotherapy for haematological malignancies, including refractory acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL). The understanding of CLL biology is changing how the disease is managed. Prognostic markers help to identify specific patient subgroups and provide insight disease progression in these groups. New studies in drugs, such as ibrutinib, target cell proliferation.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent advances in the management of mantle cell lymphoma (MCL), including rituximab maintenance after autologous stem cell transplantation in younger patients, bortezomib (Velcade)-based combinations, and lenalidomide as a single agent and in combination with rituximab (R-squared).

A summary of the new uses of immunotherapy and biomarkers in the treatment of NSCLC by Dr. Nayer Rizvi

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Peter Hillmen (Leeds General Infirmary, UK) about recent advances in the research of chronic lymphocytic leukaemia (CLL). Balancing treatment efficacy versus toxicity is important and there is reference to the CLL10 study. Anti-CD1 monoclonal antibody therapy after completing chemotherapy, the 17p deletion, allogeneic transplants and a ‘chemo-free’ approach are also considered.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses recent advances in the management of patients with mantle cell lymphoma (MCL). Rituximab maintenance after autologous haematopoietic stem cell transplantation resulted in prolonged progression-free survival. Ibrutinib is being considered for frontline treatment in MCL.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Robin Foà (Sapienza University, Rome, Italy) discusses how understanding disease biology leads to targeted therapies in different types of leukaemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses multiple myeloma and amyloidosis. In multiple myeloma, minimum residual disease (MRD) testing is receiving great interest in the evaluation of treatment and as a prognostic marker. In amyloidosis, proteasome inhibition is emerging as an important novel therapy.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses a phase II trial of interim positron emission tomography (PET) scan-tailored therapy in advanced-stage diffuse large B-cell lymphoma.

Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses results of recent clinical studies in Hodgkin lymphoma (HL) presented at the 2014 American Society of Hematology (ASH) Annual Meeting, including brentuximab vedotin in combination with other agents, positron emission tomography (PET) for tailored treatment and PD-1 immune checkpoint inhibitors.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) discusses the development of therapies with novel monoclonal antibodies in multiple myeloma, including antibodies that target CD38, CS1 and PD-1.

Dr George Follows provides an overview of results of clinical trials in chronic lymphocytic leukaemia (CLL) presented at the 2014 American Society of Hematology (ASH) Annual Meeting. He considers the clinical value of maintenance therapy with anti-CD20 monoclonal antibodies in CLL and molecularly defined subtypes of CLL.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the preliminary results of a phase Ib study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukaemia (CLL).

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the first interim analysis of the phase III prospective Lyma study of rituximab maintenance versus wait and watch after four courses of rituximab, dexamethasone, cytarabine and cisplatin (R-DHAP) followed by autologous stem cell transplantation (ASCT) in previously untreated young patients (under 66 years old) with mantle cell lymphoma.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses the molecular approach in managing diffuse large B-cell lymphoma (DLBCL). The molecularly defined DLBCL subtypes, germinal centre B-cell-like (GCB)-DLBCL and activated B-cell-like (ABC)-DLBCL, have important clinical implications.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta isoform (P110?), idelalisib, in the management of haematological malignancies, including lymphoma and chronic lymphocytic leukaemia (CLL). Idelalisib is considered in combination with other therapies to enhance efficacy endpoints.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the final analysis of the RO-CHOP phase Ib/II study of the histone deacetylase inhibitor, romidepsin, in association with cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (CHOP) in previously untreated patients with peripheral T-cell lymphoma.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses the investigational approaches of brentuximab vedotin, an anti-CD30 antibody conjugated to a cytostatic microtubule-disrupting agent, in the treatment of previously untreated and refractory/relapse patients with Hodgkin lymphoma.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses a phase I study of the novel PI3k-?,? inhibitor, duvelisib (IPI-145), in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Sunil Verma and Dr. Nadia Califaretti discuss case studies in breast cancer.

OncologyEducation.com presents: The CONCORD-2 study aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, in order to inform global policy on cancer control.

OncologyEducation.com presents: The CONCORD-2 study aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, in order to inform global policy on cancer control.

Armando and Jordan Lastra A Fathers Cancer and a Sons Careerbrought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Rob Rutigliano Testicular Cancer Would be Devastated if NSHOA closed brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Jeffrey Vacirca, MD – CConquering Cancer Close to Home brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the National Lung Matrix trial, which is a collaboration between Cancer Research UK, AstraZeneca and Pfizer. This approach aims to improve the interaction between academia and industry, thereby facilitating the development of molecularly defined treatments in lung cancer.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the ongoing phase I/II AURA study of the epidermal growth factor receptor (EGFR) inhibitor, AZD9291, in patients with advanced non-small cell lung cancer (NSCLC) and disease progression while on a previous continuous treatment with an EGFR inhibitor.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Rachel Humphrey (Senior Vice President, Head of Immuno-Oncology, AstraZeneca) discusses the anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, MEDI4736, which is being evaluated in phase I/II studies in patients with various advanced solid tumour types. The combination of MEDI4736 with the anti-cytotoxic T-lymphocyte-associated protein 4 (CTL-4) monoclonal antibody, tremelimumab, is being studied in patients with non-small cell lung cancer.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the Study 19 phase II quality of life study of maintenance treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib, in patients with relapsed, high-grade, platinum-sensitive ovarian cancer.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) debates the requirement of intense treatment in relapsed multiple myeloma. Dr Landgren refers to results of the phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed multiple myeloma. Although patient outcomes have improved with these new and milder treatments, there is a need to understand patient subgroups that do not response to these treatments.

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Philippe Moreau (University Hospital of Nantes, France) discusses novel agents in the management of multiple myeloma. An open-label, multicentre, phase Ib study of the human anti-CD38 monoclonal antibody, daratumumab, in combination with backbone regimens in multiple myeloma, including bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone, is ongoing. The phase III ASPIRE study showed that addition of carfilzomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed multiple myeloma resulted in a statistically significant improvement in progression-free survival.

Thomas Mccloskey – Non Hodgkins Lymphoma Care Close to Home brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Yelda Nouri, MD – Cancer Care, an MDs view brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Rick and Carrie Yanez Husband and Wife Diagnosed With Cancer brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Dawn Savarese – What does a Chief Revenue Officer do at NSHOA? brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Ann and Bill An Ovarian Cancer Diagnosis In Sickness and in Health brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

George Calcanes – What does the Chief Clinical Officer do at NSHOA brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Marie Ships and Merrianne Van Ness Diagnosed with Lung Cancer Received so much Support from NSHOA & her Sister brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)